Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2017-08-09 Interim / Quarterly Rep…
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2017
2017-08-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 9, 2017, reporting the results of operations for the second quarter ended June 30, 2017. It mentions a press release announcing the financial results and an investor conference call to discuss the quarter's results and business outlook. The document itself is a current report filing (8-K) and does not contain the full financial statements or detailed financial analysis. It primarily serves as an announcement of the earnings release and the upcoming call. Given the document length is only 3020 characters and it references a press release and a conference call, this fits the profile of an Earnings Release (ER) announcement rather than a full Interim/Quarterly Report (IR). Therefore, the appropriate classification is Earnings Release (ER).
2017-08-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates the filing is about an announcement of a Special Protocol Assessment (SPA) agreement with the FDA regarding clinical trials. It includes a press release as an exhibit. The document is short (2934 characters) and primarily serves to announce an event rather than provide detailed financial data or a full report. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-08-01 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 16, 2017, reporting the submission of matters to a vote of security holders at the company's annual meeting. It details the voting results for director elections and approval of the independent auditor. The content focuses on official voting results from the annual meeting, not the meeting materials or the full annual report. The document length is 4149 characters, which is relatively short and consistent with a voting results announcement. Therefore, this filing corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-06-21 English
FORM-4
Director's Dealing
2017-06-20 English
FORM4
Director's Dealing
2017-06-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.